Clinical trial
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots…
NCT00224471 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00224471 |
|---|---|
| Title | Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine |
| Official title | A Phase III, Double-blind, Randomized, Study to Compare: 1) the Immunogenicity and Safety of 3 Commercial Scale Consistency Lots of GlaxoSmithKline (GSK) Biologicals' Herpes Simplex Candidate Vaccine in Healthy HSV-1 and -2 Seronegative (HSV 1-/2-) Female Subjects Aged 10 - 17 Years, and 2) Vaccine… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Herpes Simplex |
| Intervention type | Biological |
| Interventions | GSK208141 vaccine |
| Enrollment | 671 |
| Start date | Dec 1, 2003 |
| Primary completion | Sep 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 23, 2005 |
| Last update posted | Sep 21, 2016 |
| Countries | Belgium, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: